临床药物治疗杂志
臨床藥物治療雜誌
림상약물치료잡지
CLINICAL MEDICATION JOURNAL
2015年
4期
73-75
,共3页
基因分型%支架内再狭窄%氯吡格雷抵抗%阿司匹林抵抗
基因分型%支架內再狹窄%氯吡格雷牴抗%阿司匹林牴抗
기인분형%지가내재협착%록필격뢰저항%아사필림저항
genotyping%in-stent restenosis%clopidogrel resistance%aspirin resistance
目的:探讨基因分型在经皮冠状动脉介入(PCI)术后支架内再狭窄患者个体化治疗中的作用.方法:为1例PCI术后发生支架内再狭窄的患者检测与抗血小板治疗相关的基因型,依据基因分型、药物相互作用等方面制定个体化治疗方案并随访1年.结果:用药方案调整后,患者病情好转,生活质量明显改善,1年内未发生任何不良心血管事件及药物不良反应.结论:依据基因型和药物相互作用等因素综合为患者实施个体化给药,可降低患者血栓形成和出血的风险,保障患者用药安全、有效,值得临床推荐.
目的:探討基因分型在經皮冠狀動脈介入(PCI)術後支架內再狹窄患者箇體化治療中的作用.方法:為1例PCI術後髮生支架內再狹窄的患者檢測與抗血小闆治療相關的基因型,依據基因分型、藥物相互作用等方麵製定箇體化治療方案併隨訪1年.結果:用藥方案調整後,患者病情好轉,生活質量明顯改善,1年內未髮生任何不良心血管事件及藥物不良反應.結論:依據基因型和藥物相互作用等因素綜閤為患者實施箇體化給藥,可降低患者血栓形成和齣血的風險,保障患者用藥安全、有效,值得臨床推薦.
목적:탐토기인분형재경피관상동맥개입(PCI)술후지가내재협착환자개체화치료중적작용.방법:위1례PCI술후발생지가내재협착적환자검측여항혈소판치료상관적기인형,의거기인분형、약물상호작용등방면제정개체화치료방안병수방1년.결과:용약방안조정후,환자병정호전,생활질량명현개선,1년내미발생임하불양심혈관사건급약물불량반응.결론:의거기인형화약물상호작용등인소종합위환자실시개체화급약,가강저환자혈전형성화출혈적풍험,보장환자용약안전、유효,치득림상추천.
Objective:To explore the role of genotyping in individualized therapy of the patient with in-stent restenosis after percutaneous coronary intervention.Methods: The clinical pharmacist tested the genotype associated with antiplatelet treatment for the patient, developed appropriate individualized treatment plans according to the genotyping and drug interactions and followed up the patient for 1 year.Results:After the adjustment of the medication, the quality of the patient's life improved signiifcantly without any adverse cardiovascular events or adverse drug reactions within one year.Conclusion: The safe and effective individualized therapy for patients can be implemented according to genotyping and drug interactions, which could reduce the risk of thrombosis and hemorrhage of patients and be worthy to clinical recommendation.
